Press Archive

Focus on innovative strength, competitive strength and process efficiency. The HARTMANN GROUP is starting to implement a new five-year strategic program to strengthen its competitiveness and secure a leading international market position in the three core segments of Wound, Incontinence and Infection Management.

Hartmann moves to extend its product portfolio for advanced wound care with strategic investment in silicone technology and innovations // Safran Coating is one of Europe’s leading and most innovative suppliers of silicone technologies for healthcare, a main driver for growth in advanced wound care

The HARTMANN GROUP, one of the leading international suppliers of medical and hygiene products, increased sales revenues by 3.7% to EUR 1.075 billion in the first half of 2019. All segments generated higher sales. The Wound Management segment has developed particularly dynamically and was an additional growth factor. With innovative wound care treatment concepts, we were able to exceed the average sales growth achieved by the HARTMANN GROUP. EBIT declined overall to EUR 53.4 million (previous year: EUR 61.1 million), a development attributable in particular to the anticipated rise in the price of important raw materials and exchange rate trend.

Sales revenues in all segments are up on the previous year – above-average growth in Wound Management driven by innovations / EBIT at EUR 30.6 million virtually the same as last year (EUR 31.3 million) / Targets confirmed for the 2019 year as a whole – focus remains on strengthening competitive position and customer orientation

The HARTMANN GROUP has coped well with the global market challenges during the 2018 financial year. Despite an unfavorable exchange rate development, persistently high regulatory expenses and increasing pressure on prices and margins across the industry, an increase in sales of 2.9 % and, influenced by these challenges, an EBIT of EUR 123.2 million were achieved.

From January to September 2018, the HARTMANN GROUP, a leading international supplier of medical and hygiene products, increased group sales to EUR 1,563.9 million, despite difficult market conditions. This reflects a moderate increase of 3.2 percent compared to the previous year.

The Supervisory Board of the HARTMANN GROUP today announced the appointment of Britta Fuenfstueck as the company’s new Chief Executive Officer and Chair of HARTMANN’s Management Board. Fuenfstueck will succeed Andreas Joehle, who has been in office since 2013 and announced last year his plans to step down due to personal reasons. She will join the Management Board of HARTMANN on November 1, 2018 and will succeed Joehle as CEO on January 1, 2019.

The HARTMANN GROUP made a positive start in its anniversary year, 2018. Propelled by innovative product solutions and LINDOR's sales in the incontinence management segment, the Group's sales revenues rose to €516.0 million in the first quarter of 2018, an increase of 2.3 percent compared to the previous year. Without the negative impact of adverse exchange rates in America and Asia due to the strength of the euro, the rise in sales would have amounted to around 4 percent. Earnings before interest and taxes (EBIT) were in line with expectations at €31.3 million.

More than 50 percent of nurses in Germany are thinking of leaving their jobs due to the current professional environment. This has been revealed by the HARTMANN GROUP’s Pflexit-Monitor, provider of medical and nursing products. The company will be supporting the German Nursing Day from March 15-17, 2018.

"With targeted investments in the future and holistic healthcare solutions, we were able to increase Group sales by 3.6% during the 2017 financial year to €2.06 billion. This means we are building on the growth rates of previous years," explains Andreas Joehle, Chief Executive Officer of the HARTMANN GROUP.

Heidenheim, Germany - November 7, 2017. In the first nine months of 2017, the HARTMANN GROUP, a leading international supplier of medical and healthcare products, succeeded in increasing its group sales revenues to EUR 1,514.7 million, a rise of 3.2% in relation to the prior year, despite difficult market conditions.

Heidenheim, Germany - September 4, 2017. Recognized for their remarkable contributions in wound care, the nominees for HARTMANN’s first LINK® Award were announced in anticipation of the LINK® Wound Healing Congress on Sept. 19th in Belfast. The congress will give health care professionals the opportunity to network and exchange knowledge on wound care.

Heidenheim, Germany - August 9, 2017. In the first six months of 2017, the HARTMANN GROUP, a leading international supplier of medical and healthcare products, achieved sales revenues of EUR 1,006.8 million and exceeded the prior-year figure by 3.4%, thus passing the one billion mark for the first time ever within a half-year period. As expected, growth in the second quarter was more restrained, due to among other things, changes in product range, connected with pending market launches within the Incontinence Management segment. Because of investments in growth, as reflected in particular in the greater expenditure for sales and marketing and the higher cost of raw materials and expenses for regulatory issues, the earnings before interest and taxes (EBIT) were slightly lower at EUR 65.4 million (prior year: EUR 68.6 million). The Group's consolidated net income of EUR 45.4 million is nevertheless at the same level as last year (EUR 45.3 million).

Heidenheim, Germany – July 3, 2017. The HARTMANN GROUP, a leading international supplier of medical and hygiene products, is pleased to announce that on July 1 the acquisition of Procter & Gamble’s (P&G) Lindor, one of the most well-known adult incontinence brands in Spain and Portugal, has successfully been completed.

Heidenheim, Germany - May 3, 2017. In the first quarter of 2017, the HARTMANN GROUP, a leading international supplier of medical and healthcare products, achieved a moderate rise of 4.5% in sales revenues to EUR 504.2 million. Meanwhile, all business segments exceeded their previous year's figure. EBIT showed a slight improvement to EUR 37.3 million (previous year: EUR 37.0 million). The Group's consolidated net income of EUR 25.1 million was in the same region as last year (EUR 25.0 million).

Heidenheim, Germany - March 28, 2017. The HARTMANN GROUP, a leading international supplier of medical and personal care products, followed up on the dynamics of the previous year with an organic growth rate of 3.3% in 2016, surpassing the benchmark set in 2015 across all segments. Taking into account negative currency effects, as well as acquisitions and divestments, consolidated sales rose by 2.3% to EUR 1,986.5 million.

Winning the top award in the ‘Most Innovative New Dressing’ category at the Journal of Wound Care Awards 2017, HydroClean® plus is recognized for changing the way wounds are treated and for its impact on patients’ lives.

Heidenheim, 22 February 2017. Incontinence pants, pull-ups and pads: these were the categories used by Stiftung Warentest in their testing of incontinence products, to be published in tomorrow's edition of the magazine. The MoliCare and MoliForm products by PAUL HARTMANN AG, a leading international provider of medical and care products, take top places in two categories. The products were assessed almost exclusively by incontinence sufferers using an applied testing procedure. The results therefore reflect a real life situation, not laboratory values.

HEIDENDHEIM, Germany – Mar.02,2017 – The HARTMANN GROUP, a leading international supplier of medical and hygiene products, announced today, it plans to acquire Procter & Gamble’s Lindor -- one of the most well-known adult incontinence brands in the Spain and Portugal professional channel. The transaction seeks to take place by end of second quarter of fiscal year 2017 and is subject to approval by local antitrust authorities.